UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma

Barata, PC; De Liano, AG; Mendiratta, P; Crolley, V; Szabados, B; Morrison, L; Wood, L; ... Rini, BI; + view all (2018) The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. British Journal of Cancer , 119 (2) pp. 160-163. 10.1038/s41416-018-0104-z. Green open access

[thumbnail of The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma.pdf]
Preview
Text
The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma.pdf - Published Version

Download (315kB) | Preview

Abstract

Background: The outcome of patients who progress on front-line immune-based combination regimens (IC) including immune checkpoint inhibitors (CPI) and receive subsequent systemic therapy is unknown. / Methods: Retrospective analysis of consecutive patients with clear-cell mRCC who progressed on one of seven clinical trials investigating an IC and received ≥1 line of subsequent VEGFR TKI therapy. / Results: Thirty-three patients [median age 57 (37–77), 85% male, 73% ECOG 0] were included. For evaluable patients (N = 28), the best response to first subsequent therapy was 29% partial response, 54% stable disease, and 18% progressive disease. The median PFS (mPFS) for first subsequent therapy was 6.4 months (95% CI, 4.4–8.4); no difference in mPFS by prior type of IC (VEGFR TKI-CPI vs. CPI-CPI) was noted (p = 0.310). Significant AEs were observed in 30% of patients, more frequently transaminitis (9%). / Conclusions: VEGFR TKIs have clinical activity in mRCC refractory to IC therapy, possibly impacted by the mechanism of prior combination therapy.

Type: Article
Title: The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma
Open access status: An open access version is available from UCL Discovery
DOI: 10.1038/s41416-018-0104-z
Publisher version: https://doi.org/10.1038/s41416-018-0104-z
Language: English
Additional information: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Keywords: Cancer, Renal cancer
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: https://discovery.ucl.ac.uk/id/eprint/10110708
Downloads since deposit
54Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item